Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.

Creative Commons License

Jackson A. M., Jhund P. S., Anand I. S., Düngen H., Lam C. S. P., Lefkowitz M. P., ...More

European heart journal, vol.42, no.36, pp.3741-3752, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 42 Issue: 36
  • Publication Date: 2021
  • Doi Number: 10.1093/eurheartj/ehab499
  • Journal Name: European heart journal
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.3741-3752
  • Keywords: Heart failure, Preserved ejection fraction, Sacubitril-valsartan, Blood pressure, DOUBLE-BLIND, BLOOD-PRESSURE, RECEPTOR, NEPRILYSIN, SPIRONOLACTONE, INHIBITOR, LCZ696, DOXAZOSIN, PLACEBO
  • Dokuz Eylül University Affiliated: Yes


Aims Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on 'apparent resistant hypertension' in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacubitril-valsartan with valsartan.